The antitachycardia pacing ICD: impact on patient selection and outcome

Implantable cardioverter defibrillator shock reduction using new antitachycardia pacing therapies

The main purpose of ICDs is to abort sudden death by delivering therapy at the moment of tachycardia. Shocks accomplish this goal but are painful. Alternatively antitachycardia pacing is painless and if deemed safe may be reasonable substitute. Multiple trials show a high efficacy rate by ATP (78-94%) for treating VTs below 200 bpm. ATP has had less efficacy for faster VTs (41-79%) and have higher probability of accelerating tachycardia (5-55%). The PainFREE trials address these issues. The first pilot study PainFREE Rx applied standardized VT detection and ATP regimen to 220 patients with 1100 spontaneous episodes of VT. ATP success for slow VT success was 92% and fast VT > 188 bpm raw success rate was 89%. None of these trials randomize shock versus ATP so comparative safety data was missing. Thus, the PainFREE Rx II trial was designed to make direct safety comparison between shock and ATP therapies for fast VT > 188 bpm. It included 634 patients with either ischemic or nonischemic cardiomyopathy followed for 1 year yielding 1760 episodes of slow VT, fast VT plus VF. The results of the PainFREE Rx II trial showed that a single regimen of ATP, burst pace 8 pulses at 88% VT cycle length could safely terminate 77% of fast VT and 90% of slow VT. Consequently, shocks were reduced by 70% compared to the shock group. Furthermore, ATP was proven safe because there was no increase in sudden death, syncope or even arrhythmia acceleration compared to shock. The quality of life of the ATP group was found to be superior to the shock group validating ATP's intent. Secondary yet important findings also included the fact that by programming the ICD to wait for 18 beats in PainFREE Rx II before treating an episode reduced markedly the number of episodes treated when compared to 12 beat detection as done in PainFREE Rx I. Since syncope occurred in only 1% of episodes, the authors suggested that a longer wait for ICD detection needs to be evaluated.

Current status of the implantable cardioverter-defibrillator

Clinical trials have established the superiority of the implantable cardioverter-defibrillator (ICD) over antiarrhythmic drug therapy in survivors of sudden cardiac death and in high-risk patients with coronary artery disease. The ICD has evolved to overcome the limitation of earlier devices that required thoracotomy for implantation and were fraught with inappropriate shock delivery. Current ICDs are implanted in a similar manner to cardiac pacemakers and incorporate sophisticated rhythm-discrimination algorithms to prevent inappropriate therapy. Managing the patient with an ICD requires an understanding of the multiprogrammable features of modern devices. Drug interactions and potential sources of electromagnetic interference may adversely affect ICD function. Driving restrictions may be necessary under certain conditions. The cost-effectiveness of ICD therapy appears favorable, given the marked survival benefit seen in randomized trials relative to antiarrhythmic drug treatment. The growing number of ICD recipients necessitates an understanding of the specialized features of the modern ICD and the role of device therapy in clinical practice.

Leakage of energy to the body surface during defibrillation shock by an implantable cardioverter-defibrillator (ICD) system--experimental evaluation during defibrillation shocks through the right ventricular lead and the subcutaneous active-can in canines

The leakage of electrical current to the body surface during defibrillation shock delivery by an implantable cardioverter-defibrillator (ICD) device (the Medtronic Jewel Plus PCD system) was evaluated in 5 dogs. The defibrillation shocks were delivered between the active-can implanted in the left subclavicular region and the endocardial lead placed in the right ventricle at the energy levels of 1, 2, 8, 12, 24 and 34 J. During each delivery, the electrical current leakage from the body surface was measured by electrodes connected to a circuit at 4 recording positions: (A) parallel-subcutaneous (the electrodes were fixed in the subcutaneous tissue of the left shoulder and the right lower chest, and the direction of the electrode vector was parallel to the direction of the defibrillation energy flow); (B) cross-subcutaneous (the electrodes were fixed in the subcutaneous tissue of the right shoulder and the left lower chest, and the vector of the electrodes was roughly perpendicular to the direction of the energy flow); (C) parallel-surface (the electrodes were fixed with ECG paste on the shaved skin surface at the left shoulder and the right lower chest); and (D) surface grounded (the electrodes were fixed on the shaved skin surface at the left shoulder and the left foot, which was grounded). The circuit resistance was set at a variable level (100-5,000 ohms) in accordance with the resistance measured through each canine body. Leakage energies were measured in 750 defibrillation shocks with each circuit resistance in 5 dogs. The leakage energy increased in accordance with the increase of the delivered energy and the decrease of the circuit resistance in all 4 recording positions. When the circuit resistance was set at 1,000 ohms, the leakage energy during shock delivery at 34 J was 32+/-17 mJ at position A, 5+/-9 mJ at B, 10+/-9 mJ at C, and 4+/-3 mJ at D (p=0.042). The peak current was highest at position A and was 87+/-22 mA with a circuit resistance of 1,000 ohms. The power of the leakage energy depended on the delivered energy and the impedance between the electrodes. The angle between the alignment of the recording electrodes and the direction of the energy flow was another important factor in determining the leakage energy. Although the peak current of the leakage energy reached the level of macro shock, the highest leakage energy from the body surface was considerably less because of the short duration of the shock delivery.

Relation of induced to spontaneous ventricular tachycardia from analysis of stored far-field implantable defibrillator electrograms

Predischarge testing of implantable cardioverter-defibrillators is often used to tailor antitachycardia pacing algorithms based on the response of induced ventricular tachycardia (VT) to pacing. Despite this practice, little is known about the relation between VT induced at predischarge study and VT that occurs spontaneously. To clarify this relation, we identified 19 patients with VT induced at predischarge study and compared the characteristics of the induced VT with the first episode of spontaneous VT. VT morphology, tachycardia cycle length, and response to antitachycardia pacing were measured from far-field electrograms stored by the implantable cardioverter-defibrillator. All subjects had coronary artery disease and previous myocardial infarction. The mean time from baseline study until a spontaneous VT episode was 162+/-121 days. Analysis of far-field electrograms revealed that spontaneous VT was morphologically different from predischarge-induced VT in 13 of 19 cases (68%). The cycle length of induced VT was significantly shorter than spontaneous VT when VT morphologies were different but not when spontaneous and induced VT had an identical morphology. Antitachycardia pacing was effective in terminating 18 of 19 (95%) induced VTs and 14 of 18 (78%) spontaneous VTs. Antitachycardia pacing was effective in terminating 9 of 12 episodes of morphologically different spontaneous VTs and 5 of 6 episodes of morphologically identical spontaneous VTs (p = NS). Thus, the characteristics of VT induced at predischarge study correlate poorly with those of subsequent spontaneous VT episodes due to the induction of faster "nonclinical" VTs at predischarge testing. This may limit the applicability of predischarge testing in tailoring antitachycardia pacing algorithms.

Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: a prospective study including 200 patients

BACKGROUND

Implantable cardioverter-defibrillators (ICDs) reduce the risk of sudden cardiac death. The objective of this study was to evaluate whether testing of antitachycardia pacing (ATP) for induced ventricular tachycardias (VTs) at predischarge examination can predict ATP success during follow-up.

METHODS AND RESULTS

The study covers 200 consecutive patients who received ICD implants from June 1991 through December 1995. All underwent electrophysiological testing. In 54 patients (ATP tested, group T), ATP terminated induced VTs successfully. In 146 patients (empirically programmed ATP, group E), only ventricular fibrillation could be induced, including 18 with unsuccessful ATP attempts for induced VTs. Disregarding the results of ATP testing, the same ATP scheme was programmed in all patients: three attempts of autodecremental ramp with 81% of the VT cycle length, with 8 to 10 pulses. During a follow-up of 20.4 +/- 10 months, 95% of 3819 spontaneous VTs were successfully terminated with ATP in 42 patients of group T. In group E, 90% of 1346 spontaneous VTs in 81 patients were terminated with ATP. Acceleration after ATP occurred in 2% in group T versus 5% in group E. The success for all episodes in individual patients was > or =90% in >60% of the ATP tested and empirically programmed patients.

CONCLUSIONS

The results of this 200-patient prospective study comparing tested versus empirical ATP show high success (95% versus 90%) for VT termination, with low rates of acceleration. ATP is safe and very effective and should be programmed "on" in all patients regardless of the predischarge EP inducibility.

Antitachycardia pacing: which patients and which methods?

This article is a review on the value of antitachycardia pacing in patients with implantable cardiac-defibrillators (ICD). Antitachycardia pacing is highly effective in terminating monomorphic ventricular tachycardias, with a success rate of 80-90%. Which algorithm is used for termination seems to be of less importance, with respect to both efficacy and safety. Spontaneous episodes of ventricular tachycardia are slower and more easily convertible than those induced by programmed stimulation. It is thus possible that fine-tuning of the antitachycardia pacing algorithm, using induced episodes, is of limited value with respect to efficacy during follow-up. Prospective studies need to be performed to resolve this issue. Spontaneous monomorphic ventricular tachycardia can also occur in patients who are noninducible. Antitachycardia pacing should therefore also be considered for such patients. Inappropriate therapy, most often due to supraventricular arrhythmias, has been reported in up to 25% of patients. The sensitivity and specificity of algorithms developed to differentiate supraventricular from ventricular tachycardias still require validation.

Results of delivered therapy for VT or VF in patients with third-generation implantable cardioverter defibrillators

Third-generation implantable cardioverter defibrillators (ICDs) offer tiered therapy and can provide significant advantage in the management of patients with life-threatening arrhythmias. Three different types of ICDs were implanted in 21 patients with ventricular tachycardia (VT) or ventricular fibrillation (VF). Arrhythmia presentation was VT (76%), VF (10%), or both (14%). The mean left ventricular ejection fraction for the group was 32.4 +/- 7%. No surgical mortality occurred. Prior to discharge individual EPS determined the final programmed settings of the ICDs. During a mean follow-up of 13 +/- 1.4 months (range 2-20) the overall patient survival was 85.7%. No sudden arrhythmic or cardiac death occurred. Twenty of 21 patients (95%) received therapy by their device. In 14 patients (67%) antitachycardia pacing (ATP) was programmed "on," 13 of which was self-adaptative autodecremental mode. There were 247 VT episodes, 231 of which were subjected to ATP with 97% success and 3% acceleration or failure. Low energy shocks reverted all other VT episodes. VF episodes were successfully reverted by a single shock (93%), two shocks (6%), or three shocks (1%). We conclude that ATP therapy of VT is successful in the large majority of episodes with rare failures, and that VF episodes are generally terminated by a single ICD shock.